Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 19;10(3):373.
doi: 10.3390/pathogens10030373.

Acinetobacter baumannii Antibiotic Resistance Mechanisms

Affiliations
Review

Acinetobacter baumannii Antibiotic Resistance Mechanisms

Ioannis Kyriakidis et al. Pathogens. .

Abstract

Acinetobacter baumannii is a Gram-negative ESKAPE microorganism that poses a threat to public health by causing severe and invasive (mostly nosocomial) infections linked with high mortality rates. During the last years, this pathogen displayed multidrug resistance (MDR), mainly due to extensive antibiotic abuse and poor stewardship. MDR isolates are associated with medical history of long hospitalization stays, presence of catheters, and mechanical ventilation, while immunocompromised and severely ill hosts predispose to invasive infections. Next-generation sequencing techniques have revolutionized diagnosis of severe A. baumannii infections, contributing to timely diagnosis and personalized therapeutic regimens according to the identification of the respective resistance genes. The aim of this review is to describe in detail all current knowledge on the genetic background of A. baumannii resistance mechanisms in humans as regards beta-lactams (penicillins, cephalosporins, carbapenems, monobactams, and beta-lactamase inhibitors), aminoglycosides, tetracyclines, fluoroquinolones, macrolides, lincosamides, streptogramin antibiotics, polymyxins, and others (amphenicols, oxazolidinones, rifamycins, fosfomycin, diaminopyrimidines, sulfonamides, glycopeptide, and lipopeptide antibiotics). Mechanisms of antimicrobial resistance refer mainly to regulation of antibiotic transportation through bacterial membranes, alteration of the antibiotic target site, and enzymatic modifications resulting in antibiotic neutralization. Virulence factors that may affect antibiotic susceptibility profiles and confer drug resistance are also being discussed. Reports from cases of A. baumannii coinfection with SARS-CoV-2 during the COVID-19 pandemic in terms of resistance profiles and MDR genes have been investigated.

Keywords: Acinetobacter baumannii; CRAB; antibiotic; antimicrobial; extensive drug resistant; multidrug resistant; next-generation sequencing; pandrug resistant; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of antibiotic resistance in A. baumannii. Antibiotic resistance can be conferred through three main mechanisms, i.e., control of antibiotic transportation through membranes (reduction of porin permeability or increased efflux), modification of antibiotic targets, and enzymatic inactivation of the antibiotics. A = aminoglycosides; B = beta-lactams; C = chloramphenicol; F = fosfomycin; L = lincosamides; M = macrolides; MATE = multidrug and toxic compound extrusion; MFS = major facilitator superfamily; O = oxazolidinones; P = polymyxins; PBP = penicillin binding protein; Q = fluoroquinolones; R = rifamycins; RND = resistance-nodulation-division; S = diaminopyrimidines and sulfonamides; SMR = small multidrug resistance family; T = tetracyclines.

References

    1. Ayoub Moubareck C., Hammoudi Halat D. Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Antibiotics. 2020;9:119. doi: 10.3390/antibiotics9030119. - DOI - PMC - PubMed
    1. Vrancianu C.O., Gheorghe I., Czobor I.B., Chifiriuc M.C. Antibiotic resistance profiles, molecular mechanisms and innovative treatment strategies of acinetobacter baumannii. Microorganisms. 2020;8:935. doi: 10.3390/microorganisms8060935. - DOI - PMC - PubMed
    1. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. Rev. 2008;21:538–582. doi: 10.1128/CMR.00058-07. - DOI - PMC - PubMed
    1. Levy-Blitchtein S., Roca I., Plasencia-Rebata S., Vicente-Taboada W., Velásquez-Pomar J., Muñoz L., Moreno-Morales J., Pons M.J., Del Valle-Mendoza J., Vila J. Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru article. Emerg. Microbes Infect. 2018;7:119. doi: 10.1038/s41426-018-0127-9. - DOI - PMC - PubMed
    1. Nasr P. Genetics, epidemiology, and clinical manifestations of multidrugresistant Acinetobacter baumannii. J. Hosp. Infect. 2020;104:4–11. doi: 10.1016/j.jhin.2019.09.021. - DOI - PubMed

LinkOut - more resources